Federal Register / Vol. 75, No. 247 / Monday, December 27, 2010 / Notices 81277 

FOR FURTHER INFORMATION CONTACT: 

Bryan Saddler, Chief Counsel, FHFA– 

OIG, at (202) 408–2577, or 

Bryan.Saddler@fhfa.gov. 

SUPPLEMENTARY INFORMATION: The 

Federal Housing Finance Regulatory 

Reform Act of 2008 (Reform Act), which 

was passed as Division A of the Housing 

and Economic Recovery Act of 2008 

(HERA), Public Law 110–289, 122 Stat. 

2654, 2913, abolished both the Federal 

Housing Finance Board (FHFB), an 

independent agency that oversaw the 

Federal Home Loan Banks (Banks), and 

the Office of Federal Housing Enterprise 

Oversight (OFHEO), an office within the 

Department of Housing and Urban 

Development (HUD) that oversaw the 

‘‘safety and soundness’’ of Fannie Mae 

and Freddie Mac. See 12 U.S.C. 1422a, 

4502(6), 4511, 4512, 4513, 4541, 4563 

(2006); H.R. Rep. No. 110–142, at 95. 

The Reform Act established in place of 

the FHFB and OFHEO a new entity, the 

Federal Housing Finance Agency 

(FHFA), which now regulates and 

supervises Fannie Mae, Freddie Mac, 

and the 12 Banks. See Reform Act 

sections 1002, 1101, 1102, 1301, 1311; 

12 U.S.C.A. 4511, 4512, 4513 (2009). 

Section 1105 of HERA also amended 

the Federal Housing Enterprises 

Financial Safety and Soundness Act of 

1992 and the Inspector General Act of 

1978 (the IG Act), by specifying that 

there shall be established an Inspector 

General within FHFA. See 12 U.S.C. 

4517(d). FHFA–OIG is responsible for, 

among other things, conducting audits, 

investigations, and inspections of 

FHFA’s programs and operations, and 

recommending polices that promote 

economy and efficiency in the 

administration of, and prevent and 

detect fraud and abuse in, those 

programs and operations. Section 6(a)(4) 

of the IG Act authorizes the Inspector 

General to require by subpoena the 

production of all information, 

documents, reports, answers, records, 

accounts, papers, and other data and 

documentary evidence deemed 

necessary in the performance of the 

Inspector General’s function. This 

notice delegates the Inspector General’s 

subpoena issuance authority to the 

FHFA–OIG Principal Deputy Inspector 

General, the FHFA–OIG Deputy 

Inspector General for Audit, the FHFA– 

OIG Deputy Inspector General for 

Investigations & Evaluations, and the 

FHFA–OIG Chief Counsel. 

Section 552a(b)(7) of Title 5, United 

States Code, authorizes the Inspector 

General to request information protected 

by the Privacy Act for a civil or criminal 

law enforcement activity. This notice 

delegates this authority to request 

records protected by the Privacy Act for 

a civil or criminal law enforcement 

activity from the Inspector General to 

the FHFA–OIG Principal Deputy 

Inspector General, the FHFA–OIG 

Deputy Inspector General for Audit, the 

FHFA–OIG Deputy Inspector General 

for Investigations & Evaluations, and the 

FHFA–OIG Chief Counsel. 

The Inspector General has not limited 

his authority to issue subpoenas or to 

request information under 5 U.S.C. 552a 

by this delegation. Also, this delegation 

expressly prohibits further delegation or 

redelegation. 

Accordingly, the Inspector General 

delegates the following authorities: 

Section A. Authority Delegated: The 

Inspector General delegates to the 

FHFA–OIG Principal Deputy Inspector 

General, the FHFA–OIG Deputy 

Inspector General for Audit, the FHFA– 

OIG Deputy Inspector General for 

Investigations & Evaluations, and the 

FHFA–OIG Chief Counsel, the authority 

to require by subpoena the production 

of all information, documents, reports, 

answers, records, accounts, papers, and 

other data and documentary evidence 

necessary in the performance of the 

functions assigned by HERA and the 

Inspector General Act. 

Additionally, the Inspector General 

delegates to the FHFA–OIG Principal 

Deputy Inspector General, the FHFA– 

OIG Deputy Inspector General for Audit, 

the FHFA–OIG Deputy Inspector 

General for Investigations & Evaluations, 

and the FHFA–OIG Chief Counsel, the 

authority to request information under 5 

U.S.C. 552a(b)(7). 

Section B. No Further Delegation or 

Redelegation: The authority delegated in 

Section A above may not be further 

delegated or redelegated. 

Authority: Pub. L. 110–289, section 1105; 

5 U.S.C. App. 3 § 6(a)(4); 5 U.S.C. 301. 

Dated: December 14, 2010. 

Steve A. Linick, 

Inspector General. 

[FR Doc. 2010–32348 Filed 12–23–10; 8:45 am] 

BILLING CODE 8070–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Board on Radiation and 

Worker Health (ABRWH or Advisory 

Board), National Institute for 

Occupational Safety and Health 

(NIOSH) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned committee: 

Time and Date: 

11 a.m.–2 p.m., January 12, 2011 

Place: Audio Conference Call via FTS 

Conferencing. The USA toll-free, dial-in 

number is 1–866–659–0537 and the pass 

code is 9933701. 

Status: Open to the public, but without a 

public comment period. 

Background: The Advisory Board was 

established under the Energy Employees 

Occupational Illness Compensation Program 

Act of 2000 to advise the President on a 

variety of policy and technical functions 

required to implement and effectively 

manage the new compensation program. Key 

functions of the Advisory Board include 

providing advice on the development of 

probability of causation guidelines, which 

have been promulgated by the Department of 

Health and Human Services (HHS) as a final 

rule; advice on methods of dose 

reconstruction, which have also been 

promulgated by HHS as a final rule; advice 

on the scientific validity and quality of dose 

estimation and reconstruction efforts being 

performed for purposes of the compensation 

program; and advice on petitions to add 

classes of workers to the Special Exposure 

Cohort (SEC). 

In December 2000, the President delegated 

responsibility for funding, staffing, and 

operating the Advisory Board to HHS, which 

subsequently delegated this authority to the 

CDC. NIOSH implements this responsibility 

for CDC. The charter was issued on August 

3, 2001, renewed at appropriate intervals, 

most recently, August 3, 2009, and will 

expire on August 3, 2011. 

Purpose: This Advisory Board is charged 

with (a) Providing advice to the Secretary, 

HHS, on the development of guidelines 

under Executive Order 13179; (b) providing 

advice to the Secretary, HHS, on the 

scientific validity and quality of dose 

reconstruction efforts performed for this 

program; and (c) upon request by the 

Secretary, HHS, advising the Secretary on 

whether there is a class of employees at any 

Department of Energy facility who were 

exposed to radiation but for whom it is not 

feasible to estimate their radiation dose, and 

on whether there is reasonable likelihood 

that such radiation doses may have 

endangered the health of members of this 

class. 

Matters to be Discussed: The agenda for the 

conference call includes: NIOSH 10-Year 

Review of its Division of Compensation 

Analysis and Support (DCAS) Program; 

Linde Ceramics Plant SEC Petition #107 

(1954–2006); DCAS Science Issues Update; 

Subcommittee and Work Group Updates; 

DCAS SEC Petition Evaluations Update for 

the February 2011 Advisory Board Meeting; 

and Board Correspondence. 

The agenda is subject to change as 

priorities dictate. 

Because there is not a public comment 

period, written comments may be submitted. 

Any written comments received will be 

included in the official record of the meeting 


erowe on DSK5CLS3C1PROD with NOTICES
81278 Federal Register / Vol. 75, No. 247 / Monday, December 27, 2010 / Notices 

and should be submitted to the contact 

person below in advance of the meeting. 

Contact Person for More Information: 

Theodore M. Katz, M.P.A., Executive 

Secretary, NIOSH, CDC, 1600 Clifton Road 

NE., Mailstop: E–20, Atlanta, GA 30333, 

Telephone (513) 533–6800, Toll Free 1–800– 

CDC–INFO, E-mail ocas@cdc.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention, and the Agency for Toxic 

Substances and Disease Registry. 

Dated: December 20, 2010. 

Lorenzo J. Falgiano, 

Acting Director, Management Analysis and 

Services Office Centers for Disease Control 

and Prevention. 

[FR Doc. 2010–32421 Filed 12–23–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–6041–NC] 

Medicare Program: Solicitation of 

Comments Regarding Development of 

a Recovery Audit Contractor Program 

for the Medicare Part C and D 

Programs 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Request for information. 

SUMMARY: This notice presents an 

approach and requests comments on the 

provision of the Patient Protection and 

Affordable Care Act (Pub. L. 111–148), 

as amended by the Health Care and 

Education Reconciliation Act of 2010 

(Pub. L. 111–152), (collectively known 

as The Affordable Care Act (ACA)) that 

requires the expansion of the Recovery 

Audit Contractor (RAC) Program to the 

Medicare Part C and D programs. 

DATES: Comment Date: To be assured 

consideration, comments must be 

received at one of the addresses 

provided below, no later than 5 p.m. on 

February 25, 2011. 

ADDRESSES: In commenting, please refer 

to file code CMS–6041–NC. Because of 

staff and resource limitations, we cannot 

accept comments by facsimile (FAX) 

transmission. 

You may submit comments in one of 

four ways (please choose only one of the 

ways listed): 

1. Electronically. You may submit 

electronic comments on this regulation 

to http://www.regulations.gov. Follow 

the ‘‘Submit a comment’’ instructions. 

2. By regular mail. You may mail 

written comments to the following 

address ONLY: Centers for Medicare & 

Medicaid Services, Department of 

Health and Human Services, Attention: 

CMS–6041–NC, P.O. Box 8013, 

Baltimore, MD 21244–8013. 

Please allow sufficient time for mailed 

comments to be received before the 

close of the comment period. 

3. By express or overnight mail. You 

may send written comments to the 

following address ONLY: Centers for 

Medicare & Medicaid Services 

Department of Health and Human 

Services, Attention: CMS–6041–NC, 

Mail Stop C4–26–05, 7500 Security 

Boulevard, Baltimore, MD 21244–1850. 

4. By hand or courier. Alternatively, 

you may deliver (by hand or courier) 

your written comments only to one of 

the following addresses prior to the 

close of the comment period: a. For 

delivery in Washington, DC—Centers 

for Medicare & Medicaid Services 

Department of Health and Human 

Services, Room 445–G, Hubert H. 

Humphrey Building, 200 Independence 

Avenue, SW., Washington, DC 20201. 

(Because access to the interior of the 

Hubert H. Humphrey Building is not 

readily available to persons without 

Federal government identification, 

commenters are encouraged to leave 

their comments in the CMS drop slots 

located in the main lobby of the 

building. A stamp-in clock is available 

for persons wishing to retain a proof of 

filing by stamping in and retaining an 

extra copy of the comments being filed.) 

b. For delivery in Baltimore, MD— 

Centers for Medicare & Medicaid 

Services Department of Health and 

Human Services, 7500 Security 

Boulevard, Baltimore, MD 21244–1850. 

If you intend to deliver your 

comments to the Baltimore address, call 

(410) 786–9994 in advance to schedule 

your arrival with one of our staff 

members. 

Comments erroneously mailed to the 

addresses indicated as appropriate for 

hand or courier delivery may be delayed 

and received after the comment period. 

Submission of comments on 

paperwork requirements. You may 

submit comments on this document’s 

paperwork requirements by following 

the instructions at the end of the 

‘‘Collection of Information 

Requirements’’ section in this document. 

For information on viewing public 

comments, see the beginning of the 

SUPPLEMENTARY INFORMATION section. 

FOR FURTHER INFORMATION CONTACT: 

Cynthia Moreno (410) 786–1164. 

SUPPLEMENTARY INFORMATION: 

Inspection of Public Comments: All 

comments received before the close of 

the comment period are available for 

viewing by the public, including any 

personally identifiable or confidential 

business information that is included in 

a comment. We post all comments 

received before the close of the 

comment period on the following Web 

site as soon as possible after they have 

been received: http:// 

www.regulations.gov. Follow the search 

instructions on that Web site to view 

public comments. 

Comments received timely will also 

be available for public inspection as 

they are received, generally beginning 

approximately three weeks after 

publication of a document, at the 

headquarters of CMS, 7500 Security 

Boulevard, Baltimore, Maryland 21244, 

Monday through Friday of each week 

from 8:30 a.m. to 4 p.m. To schedule an 

appointment to view public comments, 

phone 1–800–743–3951. 

I. Background 

The Balanced Budget Act of 1997 

(BBA) (Pub. L. 105–33) established the 

Medicare+Choice (M+C) program. 

Under section 1851(a)(1) of the Social 

Security Act (the Act), every individual 

with Medicare Parts A and B, except for 

individuals with end stage renal 

disease, could elect to receive benefits 

either through the original Medicare 

program or an M+C plan, if one was 

offered where the beneficiary lived. The 

primary goal of the M+C program was 

to provide Medicare beneficiaries with a 

wider range of health plan choices. 

The Medicare, Medicaid, and SCHIP 

Balanced Budget Refinement Act of 

1999, (Pub. L. 106–113), amended the 

M+C provisions of the BBA. Further 

amendments were made to the M+C 

program by the Medicare, Medicaid, and 

SCHIP Benefits Improvement and 

Protection Act of 2000 (Pub. L. 106– 

554), enacted December 21, 2000. 

On December 8, 2003, the Congress 

enacted the Medicare Prescription Drug, 

Improvement, and Modernization Act of 

2003 (MMA) (Pub. L. 108–173). Title I 

of the MMA added new sections 1860D– 

1 through 1860D–42 to the Act creating 

the Medicare Prescription Drug Benefit 

(Part D) program, a landmark change to 

the Medicare program. 

Sections 201 through 241 of Title II of 

the MMA made significant changes to 

the M+C program. As directed by Title 

II of the MMA, we renamed the M+C 

program the Medicare Advantage (MA) 

program. We also revised our 

regulations to include new payment and 

bidding provisions based largely on risk, 

to recognize the addition of regional 

Preferred Provider Organization plans, 

to address the provision of prescription 


erowe on DSK5CLS3C1PROD with NOTICES